Cargando…
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a lethal thoracic malignancy whose incidence is still increasing worldwide. MPM is characterized by frequent inactivation of tumor-suppressor genes (TSGs), e.g., the homozygous deletion of CDKN2A/2B and various genetic alterations that inactivate BAP1, NF2, LA...
Autores principales: | Yang, Haitang, Xu, Duo, Schmid, Ralph A., Peng, Ren-Wang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672749/ https://www.ncbi.nlm.nih.gov/pubmed/33240401 http://dx.doi.org/10.1177/1758835920971421 |
Ejemplares similares
-
Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
por: Xu, Duo, et al.
Publicado: (2020) -
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
por: Xu, Duo, et al.
Publicado: (2019) -
Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020) -
Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021) -
Malignant pleural mesothelioma co-opts BCL-X(L) and autophagy to escape apoptosis
por: Xu, Duo, et al.
Publicado: (2021)